188 results about "Granulocyte macrophage colony-stimulating factor" patented technology

The invention provides methods and compositions for targeting a separately generated immune response to a specific organ or tissue, e.g. one affected by cancer, using one or more agents with a tropism for the organ or tissue or that can be specifically localized to the desired organ or tissue. For example, the invention provides methods ands compositions for treating liver metastases from colorectal cancer using a combination of a granulocyte/macrophage colony stimulating factor (GM-CSF) augmented tumor cell vaccination and Listeria monocytogenes (LM) infection.

The present invention relates to a method of isolating and culturing mesenchymal stem cells using umbilical cord blood that is most ideal for cell therapy. The method comprises adding an anti-coagulant to umbilical cord blood having a volume of more than 45 ml per unit, which is obtained within 24 hours after parturition; diluting the resulting mixture of the anti-coagulant and umbilical cord blood with an αMEM (alpha-minimum essential medium), followed by centrifugation to harvest monocytes; and subjecting the obtained monocytes into suspension culture in the αMEM containing Stem Cell Factor, GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-stimulating factor), IL-3 (interleukin-3) and IL-6 (interleukin-6).

The invention discloses a quantitative determination method for activity of a nerve growth factor. The method comprises the following steps of: (1) washing TF-1 cells in a logarithmic phase by a basal culture medium that contains no serum and recombined human granulocyte-macrophage colony stimulating factors, and then resuspending the TF-1 cells to obtain TF-1cell suspension liquid; (2) respectively adding the TF-1cell suspension liquid into a gradient-diluted nerve growth factor standard sample and a sample to be tested, and incubating at 37 DEG C in presence of 5% of CO2; then respectively adding an indicating agent to detect the absorbance/fluorescence value and drawing a standard curve line; and (3) calculating the activity concentration of the nerve growth factor of the sample to be tested according to the standard curve line and the absorbance/fluorescence value of the sample. The quantitative determination method for activity of the nerve growth factor disclosed by the invention has good accuracy and precision.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A tumor vaccine which comprises a microparticle or a lysate prepared from a solidified tumor material selected from the group consisting of a tumor tissue, a tumor cell, and a component thereof, and at least one cytokine and/or cytokine-inducing agent (e.g., a granulocyte-macrophage-colony stimulating factor and/or interleukin-2 and the like), and optionally an adjuvant. The vaccine can be easily prepared and widely applied for prevention of recurrence, inhibition of metastasis and therapeutic treatment regardless of a type of a tumor, and has excellent antitumor effect.

The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.

An oral sticking sheet of the recombinant human granulocyte-macrophage colony stimulating factor for treating oral ulcer is composed of a water-insoluble protecting layer and an adhesive layer containing said active medicine, adhesive, the stabilizer for stabilizing the activity of protein and percutaneous absorption promoter.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human granulocyte macrophage colony stimulating factor (GM-CSF) to result in GM-CSF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The invention provides a preparation method of a large-scale culture dendritic cell vaccine. The preparation method comprises the following process steps of: performing in-vitro separation and purification on collected white blood cells in human peripheral blood by adopting a blood cell separation machine to obtain a large number of mononuclear cells, wherein the order of magnitude can be above 10<9>; using a human granulocyte-macrophage colony stimulating factor and interleukin 4 to induce the culture to obtain a large number of immature dendritic cells, wherein the order of magnitude can be above 10<8>; and loading a tumor specific antigen in the immature dendritic cells, and then obtaining the mature dendritic cell vaccine with an anti-tumor effect under the induction culture conditions of a tumor necrosis factor alpha and lipopolysaccharides. The invention further provides a multi-time and multi-treatment course clinical application of the dendritic cell vaccine obtained through the method.

The invention discloses a use of recombinant human granulocyte macrophage colony stimulating factor in the preparation of treatment or prevention hepatitis B, while includes simultaneous or successive given recombinant human granulocyte macrophage colony stimulating factor and genetic engineering hepatitis B vaccine for the prevention or treatment of hepatitis B.

The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The modifications described herein can be used for the synthesis and application of the adducts in radio-labeling, molecular imaging and protein therapeutic applications, and the treatment of disorders such as rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type-1 diabetes, Crohn's disease, and systemic sclerosis, Alzheimer disease, cancer, liver disease (e.g., alcoholic liver disease), and cachexia.

The present invention provides a recombinant plasmid vector comprising a kanamycin resistance gene, a promoter, an endoxylanase signal sequence, a nucleotide sequence coding for an oligopeptide consisting of 13 amino acids including 6 consecutive histidine residues, and a human granulocyte colony stimulating factor(hG-CSF) gene; an E. coli transformed with the said vector; and, a process for producing complete hG-CSF protein with high purity from the protein pool secreted by the said microorganism. In accordance with the invention, the hG-CSF protein can be prepared with high purity through rather simple process facilitating secretion of large amount of hG-CSF fusion protein into the periplasm, which does not require complicated processes such as solubilization and subsequent refolding required for isolation of the hG-CSF protein produced in cytoplasm as insoluble inclusion bodies by conventional techniques, thus, the hG-CSF protein can be widely used as an active ingredient in the development of supplementary agents for anticancer therapy.

Disclosed is a method for preventing and/or soothing dry or sensitive skin against external stresses, comprising contacting the skin with a composition including an agent that decreases the release of granulocyte-macrophage colony-stimulating factor (GMCSF) from keratinocytes in the skin, wherein under conditions of external stress, dry or sensitive skin is soothed and/or prevented. Agents that decrease the release of GMCSF include silybin, piperine, tetrahydropiperine, nortrachelogenine, rhapontin, arctiin, artigenin and mixtures thereof. Also disclosed is a method of identifying an agent that decreases the level of GMCSF released from keratinocytes.

The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of wounds, ulcers, sores, burns and other injuries to the skin or mucous membranes of the body.

A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor.

The invention discloses a composition for promoting physiologically regulative regeneration of a damaged tissue. The composition comprises such components as albumin, epidermal growth factor, transforming growth factor alpha, keratinocyte growth factor, basic fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, interleukin-8 and granulocyte-macrophage colony stimulating factor. The eight protein factors are combined for use to comprehensively develop the physiological tissue repair function; the eight protein factors functionally promote each other; based on the own physiological tissue recovery mechanism of the human body, the wound healing is accelerated and the wound healing quality is improved, including recovering the structure and the functions of the normal skin tissue. Each cell factor-containing component has clear mechanism of action without any potential toxic and side effect and objectionable odor. Such a combined recovery agent is capable of recovering the normal structure and the physiological functions of tissues more quickly under the physiological conditions of the human body.

The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.

The invention discloses an AFP and GM-CSF dual-gene co-expression recombinant vector, which is sequentially linked with an AFP gene, an IRES sequence and a GM-CSF gene in a vector transcription direction, or is sequentially linked with a GM-CSF gene, an IRES sequence and an AFP gene in a vector transcription direction, wherein nucleotide sequence of the AFP gene is represented in SEQ ID NO: 1 in a sequence list, nucleotide sequence of the GM-CSF gene is represented in SEQ ID NO: 2 in the sequence list, and nucleotide sequence of the IRES sequence is represented in SEQ ID NO: 3 in the sequence list. The dual-gene co-expression recombinant vector, which links the AFP gene and the GM-CSF gene through the IRES sequence, can simultaneously express alpha fetal protein and a granulocyte-macrophage colony stimulating factor in a same vector; and the recombinant vector, in immunogene therapy of liver cancer, not only can develop an immune regulating function of a cell factor but also can generate a specific anti-tumor effect targeted for the liver cancer.